Take a look around.
Larotrectinib Delivers 81% Overall Response Rate in an Expanded Dataset of 109 TRK Fusion Cancer Patients Across Ages and Tumor Types
Bayer and Loxo Oncology, Inc. (Nasdaq: LOXO), today announced updated clinical data for larotrectinib in adult and pediatric patients with TRK fusion cancer across 24 unique tumor types. The...Learn more
Bayer U.S. Appoints Scott Partridge General Counsel
Scott Partridge, former vice president of global strategy for Monsanto, now part of Bayer, has been named the company's U.S. General Counsel. Partridge, who succeeds former General Counsel Jan...Learn more
Explore Our Divisions
In line with our mission “Bayer: Science for A Better Life,” we aim to improve people’s quality of life.